Clinical value of integrated [18F]fluoro- 2-deoxy-D-glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma: Comparison With sonography

Journal of Ultrasound in Medicine

Volumn 30, Issue 9, 2011, Pages 1267-1273

  Choi, Woo Hee ^a   Chung, Yong An ^b   Han, Eun Ji ^a   Sohn, Hyung Sun ^a   Lee, Sang Hoon ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Papillary thyroid carcinoma; Sonography

Indexed keywords

DIAGNOSIS; ELECTRONS; GLUCOSE; PATHOLOGY; POSITRONS; TUMORS; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; FLUORO 2 DEOXY D GLUCOSE; LYMPH NODE METASTASIS; PAPILLARY THYROID CARCINOMATA; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; PROGNOSTIC FACTORS; STATISTICALLY SIGNIFICANT DIFFERENCE;

POSITRON EMISSION TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052491415     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2011.30.9.1267     Document Type: Article

References (24)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
2. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001; 28:816-821. (Pubitemid 32662543)
3. Wang W, Macapinlac H, Larson SM, et al. [18F]2-Fluoro-2-deoxy-Dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab1999; 84:2291-2302.
4. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015. (Pubitemid 30396649)
5. Jeong HS, Baek CH, Son YI, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 2006; 65:402-407.
6. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based followup after radiotherapy for head and neck cancer. Cancer 2009; 115:4586- 4594.
7. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47:616-624. (Pubitemid 46768462)
8. Choi JW, Yoon YH, Yoon YH, Kim SM, Koo BS. Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT. Ann Surg Oncol 2011; 18:1306-1311.
9. Morita S, Mizoguchi K, Suzuki M, Iizuka K. The accuracy of (18)[F]-fluoro- 2-deoxy-D-glucose-positron emission tomography/computed tomography, ultrasonography, and enhanced computed tomography alone in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma. World J Surg 2010; 34:2564-2569.
10. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26:22- 28. (Pubitemid 36918813)
11. Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007; 392:417-422. (Pubitemid 46911423)
12. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94:1162-1167.
13. Lim YC, Choi EC, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg2009; 96:253-257.
14. Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 2007; 31:2085-2091. (Pubitemid 47620236)
15. Vergez S, Sarini J, Percodani J, Serrano E, Caron P. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol 2010; 36:777-782.
16. Ahn JE, Lee JH, Yi JS, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 2008; 32:1552-1558.
17. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 2008; 18:411-418. (Pubitemid 351519549)
18. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009; 193:871-878.
19. Sohn YM, Kwak JY, Kim EK, Moon HJ, Kim SJ, Kim MJ. Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy. AJR Am J Roentgenol 2010; 194:38-43.
20. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 2007; 14:730-738. (Pubitemid 46175319)
21. Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J 2009; 56:177-192.
22. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003; 64:227-237. (Pubitemid 37203463)
23. Um SW, Kim H, Koh WJ, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I nonsmall cell lung cancer. J Thorac Oncol 2009; 4:1331-1336.
24. Namura K, Minamimoto R, Yao M, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDGPET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010; 10:667.